NCT06040541 Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
| NCT ID | NCT06040541 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Revolution Medicines, Inc. |
| Condition | Non-small Cell Lung Cancer (NSCLC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 604 participants |
| Start Date | 2023-09-07 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 604 participants in total. It began in 2023-09-07 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Eligibility Criteria
Inclusion Criteria: * Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation * Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage * ECOG performance status 0 or 1 * Adequate organ function Exclusion Criteria: * Primary central nervous system (CNS) tumors * Known or suspected leptomeningeal or active brain metastases or spinal cord compression * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication * Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors) Other inclusion/exclusion criteria may apply.
Contact & Investigator
Revolution Medicines, Inc.
STUDY DIRECTOR
Revolution Medicines, Inc.
Frequently Asked Questions
Who can join the NCT06040541 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-small Cell Lung Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06040541 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06040541 currently recruiting?
Yes, NCT06040541 is actively recruiting participants. Contact the research team at medinfo@RevMed.com for enrollment information.
Where is the NCT06040541 trial being conducted?
This trial is being conducted at Sacramento, United States, New Haven, United States, Sarasota, United States, Tampa, United States and 11 additional locations.
Who is sponsoring the NCT06040541 clinical trial?
NCT06040541 is sponsored by Revolution Medicines, Inc.. The principal investigator is Revolution Medicines, Inc. at Revolution Medicines, Inc.. The trial plans to enroll 604 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.